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Abstract 
Background: The purpose of the present study is to investigate the expression levels of STAT3, 
pSTAT3, MMP-7 and VEGF in colorectal adenocarcinoma, and also to determine association with 
the clinico-pathological parameters and co-expression of these genes. Methods: An immunohisto-
chemical method was used to evaluate the expression of MMP-7 and VEGF genes in 93 archival 
tissues whereas STAT3 and pSTAT3 expression was determined in 75 cases. Results: Overexpres-
sion of STAT3 was detected in 26.7% (20/75), pSTAT3 in 13.4% (10/75), MMP-7 in 38.8% (36/93) 
and VEGF in 59.2% (55/93) of the colorectal carcinomas. STAT3, MMP-7 and VEGF immunoposi-
tivity were significantly correlated with poorly-differentiated tumors (P = 0.004; P = 0.03; P = 
0.002, respectively) but not with other parameters. However, pSTAT3 immunostaining was not 
significantly associated with the clinico-pathological characteristics. Significant relationship was 
noted between overexpression of pSTAT3 and STAT3 (P < 0.001), pSTAT3 and VEGF (P = 0.044), 
pSTAT3 and MMP-7 (P = 0.003), and STAT3 and VEGF (P = 0.037) but marginal association was 
detected between STAT3 and MMP-7 (P = 0.057), and MMP-7 and VEGF (P = 0.052). Conclusion: 
Our data suggest that expression of these genes may have an important role in tumor dedifferen-
tiation and may be useful as indicators of biologic aggressiveness. Co-expression of the bio-
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markers by cancer cells may have important implications in colorectal cancer biology and could 
be useful biological markers of the malignant phenotype. 
 
Keywords 
STAT3, pSTAT3, MMP-7, VEGF, Colorectal Adenocarcinoma 
 
 
1. Introduction 
Signal transducer and activator of transcription 3 (STAT3) is involved in the JAK-STAT signaling pathway that 
mediates a wide variety of cellular responses depending on the tissue type such as differentiation, proliferation, 
apoptosis and survival [1]. STAT3 is constitutively activated in various human epithelial malignancies, includ-
ing prostate, breast, lung, head and neck, brain, pancreas and colorectal cancer [2]-[4] as well as haematopoietic 
malignancies [2] suggesting its importance in oncogenesis. Cellular transformation by activated STAT3 occurs 
through the transcriptional regulation of specific target genes including those encoding the anti-apoptotic pro-
teins Bcl-xl, Mcl-1, and Bcl-2, the proliferation-associated proteins Cyclin D1 (CCND1) and Myc, and the pro- 
angiogenic factor VEGF [2] [5] [6]. Activation of STAT3 also contributes to invasive growth of cancer cells and 
confers resistance to chemotherapy [3] [7]. Elevated levels of STAT3 were significantly associated with poor 
prognosis [8] [9] and metastasis [3] in colorectal carcinomas (CRCs).  
The matrix metalloproteinases (MMPs) family consists of proteolytic enzymes that are involved in the degra-
dation of extracellular matrix components [10]. MMPs are often overexpressed during tumor progression and 
have been associated with tumor invasion and metastasis [11]. MMP-7, a member of the MMP gene family, has 
proteolytic activity against a wide range of substrates such as collagens, proteoglycans, elastin, laminin, fi-
bronectin and casein [12]. It has been reported that MMP-7 was overexpressed both in benign and malignant 
colorectal tumors [13] [14] but the level of expression in colorectal cancer was known to be 50-fold greater than 
normal mucosa [15]. It has also been reported that MMP-7 was associated in the development and progression 
of CRC, and correlates with distant and lymph node metastasis [16] [17]. 
Vascular endothelial growth factor (VEGF) plays a critical role in the process of angiogenesis by stimulating 
the proliferation and migration of vascular endothelial cells, and modelling of the tumor neovasculature. Neo- 
angiogenesis, mediated by angiogenic cytokines, contributes to the growth, progression and survival of tumors 
[18]. VEGF is a potent growth factor that stimulates a strong angiogenic response by increasing microvascular 
permeability [19]. The formation of new blood capillaries provides nutrients for rapid growth, and increases the 
opportunity for tumor cells to metastasize [18]. VEGF expression in CRC was found to be associated with poor 
prognosis and development of metastatic disease [20] [21], and could be an independent risk factor for tumor 
recurrence and might assist in selecting patients who could benefit from adjuvant therapy [22].  
Currently colorectal malignancy is an important disease in Malaysia. The incidence of CRC is rising rapidly 
and ranked third highest in both males and females among the top ten most common cancers in Malaysia. It ac-
counts for 14.2% of male cancers and 10.1% female cancers [23]. Although a number of etiological factors have 
been identified, the genetic information on the disease among the Malaysians is unavailable. Though STAT3, 
pSTAT3, MMP-7 and VEGF have been widely studied, in the present study we select these biomarkers to de-
termine the expression pattern in colorectal adenocarcinomas using immunohistochemistry in a hospital-based 
Malaysian population. We also evaluate association with the clinico-pathological parameters such as patients’ 
age, gender, ethnicity, histological grade, Dukes’ stage and nodal status, and co-expression of these biomarkers. 
2. Materials and Methods 
2.1. Patients and Tissues 
Colorectal adenocarcinomas were collected from 93 patients who underwent CRC resection at the Hospital 
Kuala Lumpur, Kuala Lumpur; Hospital Pulau Pinang, Pulau Pinang and Hospital University Kebangsaan Ma-
laysia, Kuala Lumpur from 2003 to 2005 in Malaysia. Informed consent was obtained from the patients who 
were admitted for surgery. All the tissues were preserved in 10% buffered formalin and subsequently processed 
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for histological evaluation and immunohistochemical studies. The clinico-pathological data including patients’ 
gender, age, ethnic group, tumor grade and Dukes’ stage were obtained from the surgical and pathological 
records of each patient (Table 1). The tumors were staged according to the Dukes’ staging classification A, B, C 
and D. Tumors were histologically graded as well (Grade I), moderate (Grade II), and poorly (Grade III) diffe-
rentiated based on the predominant pattern of the tumor by a qualified pathologist. 
2.2. Immunohistochemistry 
The tissue sections of 4 μm thickness were cut from each paraffin-embedded tumor tissue blocks and placed on 
the glass slides. These blocks were obtained from the hospitals. These sections were immunostained with pri-
mary antibodies directed against STAT3 (rabbit anti-human, IgG H-190; polyclonal, Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA), pSTAT3 (rabbit anti-human IgG Tyr705; polyclonal, Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA), MMP-7 (rabbit anti-human, IgG/PUMP-1; polyclonal, Chemicon International, 
Temecula, CA, USA) and VEGF (mouse anti-human, IgG2a C-1; monoclonal, Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA), using standard immunoperoxidase method. All the procedures were performed at room 
temperature, unless otherwise specified. DAKO Envision™, Peroxidase, Mouse kit (Dako, Glostrup, Denmark) 
was used to detect the reaction of mouse anti-human antibody for VEGF, and Dako Cytomation Envision Sys-
tem-HRP Labelled Polymer Anti-Rabbit (Dako, Glostrup, Denmark) was used to demonstrate the reaction of 
rabbit anti-human against STAT3, pSTAT3 and MMP-7 proteins. 
The tissue sections were deparaffinized in xylene, rehydrated in decreasing concentration of ethanol and 
rinsed in distilled water. After a brief wash, the sections were subjected to microwave antigen retrieval treatment 
 
Table 1. Clinico-pathological data of patients with colorectal adenocarcinoma.                                               
Patients’ characteristic Total number of cases (%) (N = 93) 
Age at diagnosis  
<60 48 (51.6) 
>60 45 (48.4) 
Gender  
Female 31 (33.3) 
Male 62 (66.7) 
Ethnicity  
Malay 29 (31.2) 
Chinese 53 (57.0) 
Indian 11 (11.8) 
Histological grade  
Grade I 32 (34.4) 
Grade II 25 (26.9) 
Grade III 36 (38.7) 
Dukes’ stage  
A 9 (9.7) 
B 29 (31.2) 
C 39 (41.9) 
D 16 (17.2) 
Lymph node status (N)  
N+ 55 (59.1) 
N− 38 (40.9) 
R. Naidu et al. 
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to obtain optimal staining intensity. The sections were microwaved in 10 mM citrate buffer (pH 6.0) solution for 
STAT3, pSTAT3 and VEGF. The solution was allowed to boil for 5 minutes twice and then cooled down to the 
room temperature before washing the sections with the distilled water. Following the treatment, the sections 
were incubated with 3% hydrogen peroxide in water for 10 minutes at 37˚C to block the endogeneous perox-
idase activity. The slides were washed with distilled water and phosphate-buffered saline (PBS) pH 7.4 for 5 
minutes each. The tissue sections were incubated with anti-STAT3 (dilution 1:150), anti-pSTAT3 (1:200), anti- 
MMP-7 (1:50) and anti-VEGF (1:50) for 1 hour at room temperature in a humidified chamber. All the antibo-
dies were diluted in 1% BSA (bovine serum albumin, Sigma, St Louis, Missouri, USA). The slides were washed 
in PBS for 30 minutes. The sections were incubated with horseradish-peroxidase labelled polymer for 30 mi-
nutes at room temperature and rinsed with PBS for 5 minutes. The reactions were treated with DAB (3, 3 di-
aminobenzidine) chromogen (Dako, Glostrup, Denmark) until appropriate colour intensity was reached. The 
sections were counterstained with Harris haematoxylin for STAT3, pSTAT3, MMP-7 and VEGF by dipping for 
4 seconds. The slides were mounted in Depex and examined under the light microscope (Leica, Germany). Co-
lorectal carcinoma tissues positive for these markers were routinely used as positive controls. For negative con-
trol, the primary antibodies were substituted with PBS. 
2.3. Evaluation of Immunostaining and Statistical Analysis 
Tumor cells that exhibit cytoplasmic and/or nuclear immunoreactivity were considered as positive for STAT3 
and pSTAT3. Immunostaining present in the cytoplasm of the malignant cells was regarded as positive for 
MMP-7 and VEGF protein expression. The scoring of the tissue sections was based on the percentage of the 
stained tumor cells [24]. The expression of STAT3, pSTAT3, MMP-7 and VEGF was based on the percentage 
of malignant cells stained: 0% - 10% as negative; 11% - 25% as weakly positive, and equal or more than 26% as 
strongly positive or overexpressed. Weakly positive and negative tumors were not included in the statistical 
analysis.  
All statistical analyses were carried out by using SPSS (version 11.5, USA). Association between expression 
of the biomarkers and clinico-pathological parameters was determined by nonparametric test. Since the normal-
ity of the data was violated, the nonparametric test namely Mann-Whitney for paired parameters (age at diagno-
sis, gender, lymph node status) or Kruskall-Willis for categorical data (ethnicity, histological grade, Dukes’ 
stage) were used. The significance of co-expression of the biomarkers was analysed by Fisher’s exact test. Sta-
tistical significance was set at P < 0.05. 
3. Results 
The immunostaining of STAT3 (Figure 1(a)) and pSTAT3 (Figure 1(b)) exhibited heterogeneous staining pat-
tern. Expression of STAT3 was present either in the cytoplasm or nuclear region in colorectal tumor cells; occa-
sional staining was present in both areas. However, pSTAT3 immunoreactivity appeared to be predominant in 
the nuclear region, whereas the cytoplasmic area showed very weak immunostaining. However, intratumor ob-
servation showed some heterogeneous immunoreactivity. MMP-7 (Figure 1(c)) and VEGF (Figure 1(d)) im-
munopositivity was detected in the cytoplasm of the tumor cells. Nuclear immunoreactivity was not noted in all 
the stained tumor cells. None of the stromal cells and negative control exhibited immunopositivity.  
Overexpression of STAT3 was detected in 26.7% (20/75), pSTAT3 in 13.4% (10/75), MMP-7 in 38.8% 
(36/93) and VEGF in 59.2% (55/93) of CRCs. Tumors weakly positive for STAT3, pSTAT3, MMP-7 and 
VEGF were demonstrated in 1.3% (1/75), 1.3% (1/75), 1.1% (1/93) and 5.4% (5/93) CRCs, respectively. Tu-
mors were considered as negative for STAT3 in 72.0% (54/75), pSTAT3 in 85.3% (64/75), MMP-7 in 60.2% 
(56/93) and VEGF in 35.5% (33/93) of CRCs. 
Statistical analysis was performed to evaluate the relationship between STAT3, pSTAT3, MMP-7 or VEGF 
immunoreactivity and clinico-pathological parameters such as patients’ age, gender, ethnic group, histological 
grade, Dukes’ stage and nodal status (Table 2 and Table 3). STAT3, MMP-7 and VEGF immunopositivity were 
significantly correlated with poorly-differentiated tumors (P = 0.004; P = 0.03; P = 0.002, respectively) but not 
with other parameters. However, pSTAT3 immunostaining was not significantly associated with the clini-
co-pathological characteristics. Elevated expression of STAT3, MMP-7 and VEGF was demonstrated in 44.8%, 
41.7% and 72.2% of the poorly-differentiated tumors, and 30.0%, 56.0% and 72.0% of the moderately-differ- 
entiated tumors compared to 3.8%, 21.9% and 34.4% of the well-differentiated tumors, correspondingly. 
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Figure 1. Immunohistochemistry of poorly (a), moderately (b), (c) and well (d) differen-
tiated colorectal adenocarcinoma. Immunostaining of (a) STAT3 was noted predomi-
nantly in the cytoplasm of the epithelial cells (arrow); (b) pSTAT3 was demonstrated as 
co-existence of intense nuclear (black arrow) and very light cytoplasmic (pink arrow) 
staining of the epithelial cells; (c) MMP-7 was observed as a prominent cytoplasmic stain- 
ing in the neoplastic colonic-epithelium (arrow); and (d) VEGF was shown as predomi-
nant cytoplasmic staining in the glandular tissue (arrow). Original magnification, ×400.      
 
Co-expression between STAT3, pSTAT3, MMP-7 and VEGF genes was also analysed (Table 4). Significant 
relationship was noted between overexpression of pSTAT3 and STAT3 (P < 0.001), pSTAT3 and VEGF (P = 
0.044), pSTAT3 and MMP-7 (P = 0.003), and STAT3 and VEGF (P = 0.037) but marginal association was de-
tected between STAT3 and MMP-7 (P = 0.057), and MMP-7 and VEGF (P = 0.052). 
4. Discussion 
In the present study we have examined the expression of STAT3, pSTAT3, MMP-7 and VEGF protein by im-
munohistochemistry in a cohort of colorectal adenocarcinomas. There was overexpression of STAT3 in 26.7% 
of CRCs but smaller proportion (13.4%) of the tumors demonstrated the activated form of STAT3 (pSTAT3). 
Similarly Hbibi et al. noted that 62% and 27% of 126 CRCs were positive for STAT3 and pSTAT3, respectively 
[25]. Other investigators reported that the frequencies of overexpressed tumors range from 44% - 78% [4] [8] [9] 
[26] [27]. Interestingly, Xiong et al. reported 100% immunopositivity for both STAT3 and pSTAT3 protein in 
38 cases [28]. Significant correlation was noted between increased expression of STAT3 and the phosphorylated 
form of STAT3 which is in agreement with findings by Lassman et al. [29]. Interestingly our data showed lower 
frequency of pSTAT3 overexpression among the CRCs compared to other findings which could be attributed to 
scoring methods, random selection of patients and types of antibodies used. Our findings suggest that a propor-
tion of the tumors that overexpress STAT3 might harbour higher levels of pSTAT3 which could have important 
implications in colorectal cancer biology. 
Increased expression of STAT3 was significantly associated with high grade tumors but this was not seen for 
the phosphorylated form of STAT3. Although the association was not supported statistically, higher frequency 
of poorly-differentiated tumors (24.1%) was positive for pSTAT3 compared to moderately (10.0%) and well 
(3.8%) differentiated tumors. Overexpression of STAT3 and pSTAT3 was not associated with other clinico-pa- 
thological parameters such as age, gender, ethnicity, Dukes’ classification and nodal metastases. Contrary to our 
results, some studies showed significant correlation between pSTAT3 and presence of nodal metastases [4] [9] 
R. Naidu et al. 
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Table 2. Association between positive expression of STAT3 or pSTAT3 and clinico-pathological features in colorectal ade-
nocarcinoma patients.                                                                                           
Clinico-pathological 
features 
Total number of 
cases (n = 75) 
Number positive cases for 
STAT3 (%) (n = 20) P
* value Number positive cases for pSTAT3 (%) (n = 10) P
* value 
Patients’ age (years)      
<60 23 5 (21.7) 0.375 (NS) 3 (13.0) 0.814 (NS) 
>60 52 15 (28.8)  7 (13.5)  
Gender      
Female 35 11 (31.4) 0.507 (NS) 4 (11.4) 0.576 (NS) 
Male 40 9 (22.5)  6 (15.0)  
Ethnicity      
Malay 25 6 (24.0) 0.941 (NS) 4 (9.3) 0.818 (NS) 
Chinese 43 12 (27.9)  5 (20.0)  
Indian 7 2 (28.6)  1 (14.3)  
Histological grade      
Grade I 26 1 (3.8) 0.004 (S) 1 (3.8) 0.086 (NS) 
Grade II 20 6 (30.0)  2 (10.0)  
Grade III 29 13 (44.8)  7 (24.1)  
Dukes’ stage      
A 5 0 (0) 0.435 (NS) 0 (0) 0.064 (NS) 
B 24 7 (29.2)  2 (8.3)  
C 32 9 (28.1)  8 (25.0)  
D 14 4 (28.6)  0 (0)  
Lymph node status (N)      
N+ 46 13 (28.3) 0.550 (NS) 8 (17.4) 0.158 (NS) 
N− 29 7 (24.1)  2 (6.9)  
*Represents significance at P < 0.05; Note: S, significant at P < 0.05. NS, not significant. 
 
[25] [27] and advanced Dukes’ stage [8] [27] but not with age, gender and/or tumor grade [4] [9] [27]. In a re-
cent study, Xiong et al. showed that all the well (n = 6), moderately (n = 27) and poorly-differentiated (n = 3) 
tumors were positive for both the activated and unactivated form of STAT3 protein [28]. Though constrasting 
results were noted probably due to smaller sample size, our data suggests that upregulation of STAT3 and 
pSTAT3 in CRC could have an important role in the tumor progression as defined by its association with high 
grade tumors. 
MMP-7 is widely expressed in the epithelial tumor cells of malignant colorectal adenocarcinomas and be-
lieved to be associated with metastasis [13] [14] [30] [31]. In the current study we found that MMP-7 was over-
expressed in 38.8% of CRCs and this positive rate is comparable with previous reports of 30% to 46% [15] [17] 
[30] [32]. In a recent study with a larger sample size of 620 cases, Fang et al. reported MMP-7 immunopositivi-
ty in 88.8% of the cancer [33]. Roca and co-investigators demonstrated 81.7% of 60 CRC tumors were positive 
for MMP-7 [34]. In the present study, clinico-pathological analysis demonstrated that the frequency of MMP-7 
immunopositivity was significantly higher in moderately- and poorly-differentiated tumors compared to well- 
differentiated tumors. However, earlier studies did not observe such association [17] [34]. Some of the studies 
have evaluated expression of MMP-7 in association with clinico-pathological parameters but did not correlate 
with histological grade [15] [30] [32] [33]. There was no significant association between MMP-7 expression and 
R. Naidu et al. 
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Table 3. Association between positive expression of MMP-7 or VEGF and clinico-pathological features in colorectal ade-
nocarcinoma patients.                                                                                            
Clinico-pathological 
features 
Total number 
of cases (n = 93) 
Number positive cases for 
MMP-7 (%) (n = 36) P
* value Number positive cases for VEGF (%) (n = 55) P
* value 
Patients’ age (years)      
<60 31 8 (25.8) 0.072 (NS) 18 (58.0) 0.882 (NS) 
>60 62 28 (45.2)  37 (59.7)  
Gender      
Female 45 19 (42.2) 0.503 (NS) 28 (62.2) 0.560 (NS) 
Male 48 17 (35.4)  27 (56.3)  
Ethnicity      
Malay 29 11 (37.9) 0.975 (NS) 15 (51.7) 0.620 (NS) 
Chinese 53 21 (39.6)  33 (62.3)  
Indian 11 4 (36.4)  7 (63.6)  
Histological grade      
Grade I 32 7 (21.9) 0.030 (S) 11 (34.4) 0.002 (S) 
Grade II 25 14 (56.0)  18 (72.0)  
Grade III 36 15 (41.7)  26 (72.2)  
Dukes’ stage      
A 9 3 (33.3) 0.186 (NS) 4 (44.4) 0.477 (NS) 
B 29 15 (51.7)  20 (69.0)  
C 39 15 (38.5)  23 (59.0)  
D 16 3 (18.8)  8 (50.0)  
Lymph node status (N)      
N+ 55 18 (32.7) 0.156 (NS) 31 (56.4) 0.515 (NS) 
N− 38 18 (47.4)  24 (63.2)  
*Represents significance at P < 0.05; Note: S, significant at P < 0.05. NS, not significant. 
 
Table 4. Association between STAT3, pSTAT3, MMP-7 and VEGF protein expression in colorectal adenocarcinoma pa-
tients.                                                                                                           
 Total number of cases 
Positive (+)/ 
negative (−) 
Number positive cases for 
pSTAT3 (%) 
Number positive cases 
for MMP-7 (%) 
Number positive cases 
for VEGF (%) 
STAT3 
(n = 75)  (n = 10) (n = 27) (n = 45) 
20 + 8 (40.0) 11 (55.0) 16 (80.0) 
55 − 2 (3.6) 16 (29.1) 29 (52.7) 
  P < 0.001 (S) P = 0.057 (NS) P = 0.037 (S) 
pSTAT3 
(n = 75)   (n = 27) (n = 45) 
10 + − 8 (80.0) 9 (90.0) 
65 −  19 (23.1) 36 (55.4) 
   P = 0.003 (S) P = 0.044 (S) 
MMP-7 
(n = 93)    (n = 55) 
36 +   26 (72.2) 
57 − − − 29 (50.9) 
    P = 0.052 (NS) 
Note: S, significant at P < 0.05. NS, not significant. 
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the age, gender, ethnicity, Dukes’ staging and lymph node status of the patients. Roca and coauthors found no 
significant correlation between MMP-7 and lymph node metastases which is consistent with our findings [34]. 
In contrast, Adachi and co-investigators reported that elevated levels of MMP-7 was significantly associated 
with lymph node metastases and advanced Dukes’ stage suggesting its role in tumor metastases [15] [30]. Our 
findings suggest that overexpression of MMP-7 could be a biological indicator for aggressive characteristics of 
colorectal cancer. 
VEGF has been extensively investigated in relation to the development of novel drugs against CRCs [20]. In 
the current study, elevated levels of VEGF were demonstrated in 59.2% of CRC. Among the biomarkers eva-
luated in this study, VEGF immunopositivity was the most frequent in CRC. In a series of studies, overexpres-
sion of VEGF was detected in 45% to 70% of CRCs [21] [35]-[42] which is comparable with the present study. 
However, Khorana et al. reported lower incidence of VEGF immunopositivity (34%) [43] whereas Uner et al. 
showed higher frequency of 86% in CRCs [44]. In the present study, a significant association was observed be-
tween VEGF expression and high histological grade tumors. Although consistent with other published reports 
[40] [42], majority of the studies did not confirm the association [21] [35]-[39] [41] [44] [45]. Statistical correla-
tion was not found with Dukes’ stage and lymph node involvement which is in agreement with other reports [37] 
[44] [46]. However most of the studies have demonstrated significant correlation between VEGF immunoreac-
tivity and nodal metastases [21] [36] [39] [40] [42] [45] or advanced Dukes’ stage [36]. The patients’ characte-
ristics (age at diagnosis, gender and ethnicity) were not significantly associated with VEGF expression and sim-
ilar observation was also noted by other investigators [21] [35] [36] [38] [39] [41] [42] [45] [46]. Our observa-
tion suggests that overexpression of VEGF could be an important marker for aggressive phenotype of colorectal 
tumors. 
Apart from determining the frequencies of the genes overexpressed as well as correlation with clinico-patho- 
logical parameters we also determined co-overexpression of STAT3, pSTAT3, MMP-7 and VEGF in CRCs.  
Overexpression of STAT3 was significantly associated with VEGF but showed marginal correlation with 
MMP-7. However, the activated form of STAT3 was found to be significantly associated with MMP-7 and 
VEGF. Our data also showed that elevated levels of MMP-7 was marginally associated VEGF. Earlier studies 
have reported that pSTAT3 promotes tumor angiogenesis by acting as a direct transcriptional activator of VEGF 
and mediates expression of genes related to tumor growth and metastasis [6]. Recently, Cascio and co-investi- 
gators supported this evidence in colon cancer cells by demonstrating the binding of STAT3 to the promoter of 
VEGF [47]. Elevated levels of MMP-7 mRNA was detected in colorectal tumor tissues with activated form of 
STAT3 [3]. In addition to MMP-7, aberrant activity of STAT3 could be a major factor of local tumor progres-
sion and metastasis of colorectal cancer through upregulation of other MMPs including MMP-1, MMP-3 and 
MMP-9 [3]. This could also explain the reason that we noted pSTAT3 was significantly associated with MMP-7 
but STAT3 showed marginal association with MMP-7.  
Among the MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9 and MMP-13), MMP-7 is primarily ex-
pressed in cancer cells during tumor progression [48] and implicated in promoting angiogenesis by remodeling 
the ECM [49]. Ito et al. reported that despite increased expression of VEGF, upregulation of MMP-7 in addition 
to MMP-1 and MMP-3 may regulate the switch from vascular quiescence to angiogenesis in the human colorec-
tal tissues [50]. Furthermore, high levels of MMP-7, MMP-1 and MMP-3 along with VEGF is associated with 
increased expression of angiogenesis markers in the CRC suggesting that MMP-7 could be one of the regulators 
of VEGF activity in human colorectal cancer cells. These observations support our data that demonstrated mar-
ginal association between MMP-7 and VEGF.  
The possible reasons for the differences between the studies could be attributed to the sample size of the cases 
used in the investigations, scoring methods including variations in the threshold definitions for overexpression 
between the laboratories, selection bias with regard to recruitment of patients such as patients’ characteristics, 
ethnicity, different histopathological types of the tumors and antibodies used. These differences could alter the 
distribution of the immunopositivity that might influence the statistical power to determine the significance of 
association.  
In our study, we showed an interesting observation that STAT3, MMP-7 and VEGF were consistently associ-
ated with high grade tumors. Histological grade or tumor differentiation has been regarded as one of the predic-
tive factors associated with poor prognosis for colorectal carcinomas. Furthermore we have also demonstrated 
significant correlation between pSTAT3 and VEGF or MMP-7, with marginal association between VEGF and 
MMP-7.  
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5. Conclusion 
In conclusion, our data suggest that expression of these genes may have an important role in tumor dedifferen-
tiation and may be useful indicators of biologic aggressiveness. Co-expression of the biomarkers by cancer cells 
might have important implications in colorectal cancer biology and could be useful biological markers of the 
malignant phenotype. 
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